Non-Small Cell Lung Cancer (NSCLC)

Multidisciplinary approaches, RNA-based next-generation sequencing, and patient-specific front-line treatment decisions are all important for curating effective NSCLC treatments.

Phase 2 data support further investigation of trastuzumab rezetecan as a treatment for patients with HER2-mutant non–small cell lung cancer.

Ivonescimab demonstrated a broad prolongation of PFS across various prespecified subgroups in patients with treatment-naïve, PD-L1–positive NSCLC.

Results from the phase 3 REZOR trial show a median PFS of 19.3 months with rezivertinib vs 9.6 months with gefitinib in patients with NSCLC.

Dr. Kim shares her insights on new investigational therapies for metastatic ALK+ NSCLC that she's particularly excited about.

Dr. Garon discusses the circumstances that might lead him to switch a patient with ALK+ NSCLC from another ALK inhibitor to lorlatinib.

The observed safety profile of HA121-28 was similar to that of other multi-targeted RET tyrosine kinase inhibitors.

Combining pembrolizumab with pemetrexed met the primary end point of objective response rate in a phase 2 trial.

The survival benefit of dacomitinib was improved in real-world settings for patients with EGFR-mutant NSCLC compared with what the ARCHER 1050 trial shows.

Factors such as World Health Organization status appeared to correlate with early mortality in an elderly non–small cell lung cancer cohort.

Dr. Kim discusses her approach to selecting the next treatment for patients with ALK+ NSCLC who progress on lorlatinib, including the key factors she considers in making this decision.

Dr. Garon explains his approach to choosing between different ALK inhibitors for ALK+ NSCLC, outlining the factors that guide his selection and when he might prefer alectinib, lorlatinib, or brigatinib.

Treatment with mobocertinib produces clinically meaningful delays in time to deterioration among patients enrolled on the phase 3 EXCLAIM-2 trial.

This video segment discusses strategies for patient education and preparation for second-line treatment with RAS GTPase inhibitors, as well as therapeutic options to consider if a patient progresses on adagrasib.

This video segment explores the potential role of KRAS-targeted therapies in the frontline treatment of KRAS-positive metastatic NSCLC, highlighting considerations for specific patient populations and disease characteristics.

This video segment examines strategies for managing adverse events associated with adagrasib, comparing its safety profile to other RAS GTPase inhibitors like sotorasib, and discusses key differences, benefits, and risks that may influence treatment selection or consideration of clinical trials.

Updated, comprehensive OS results with the combination in resectable NSCLC will be shared in a future peer-reviewed setting.

Efficacy results from cohort 1 of the phase 1b Beamion LUNG-1 trial support the decision to review zongertinib in HER2-mutant advanced NSCLC.

IBI363 demonstrated encouraging efficacy and a manageable safety profile in patients with squamous NSCLC based on results from a phase 1 trial.

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Alexander Spira, MD, and Julia Lazo, RN, spoke with Melinda Reubens, who was diagnosed with EGFR-mutant NSCLC, and her husband Justin.

Dr. Garon explains the factors guiding his choice between EGFR inhibitors for EGFR+ NSCLC and when he might consider alternatives like afatinib or erlotinib.

Radiotherapy plus camrelizumab and platinum-doublet chemotherapy showed manageable toxicity in untreated non–small cell lung cancer with brain metastases.

Christine Bestvina, MD, stated that the presence of EGFR and ALK mutations can affect the way that a patient will react to treatment and should be factors that physicians consider.

6-thio-2’-deoxyguanosine sequenced plus cemiplimab elicited an OS of 16.9 months in the third-line setting for patients with advanced non–small cell lung cancer.